Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
$5.33
+1.3%		$5.13
$2.78
▼
$6.45
$427.49M0.28227,643 shs600,436 shs
CCXI
Churchill Capital Corp XI
$12.90
+6.9%		$14.39
$10.07
▼
$19.69
$920.49M1.221.57 million shs2.99 million shs
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$13.67
-1.1%		$12.26
$9.77
▼
$17.29
$2.38B0.2493,236 shs15,795 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
0.00%+0.38%-0.56%+22.25%+83.16%
CCXI
Churchill Capital Corp XI
0.00%+4.71%-8.32%+24.46%+1,289,999,900.00%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
0.00%+6.63%+8.84%+32.98%-21.80%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
$5.33
+1.3%		$5.13
$2.78
▼
$6.45
$427.49M0.28227,643 shs600,436 shs
CCXI
Churchill Capital Corp XI
$12.90
+6.9%		$14.39
$10.07
▼
$19.69
$920.49M1.221.57 million shs2.99 million shs
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$13.67
-1.1%		$12.26
$9.77
▼
$17.29
$2.38B0.2493,236 shs15,795 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
0.00%+0.38%-0.56%+22.25%+83.16%
CCXI
Churchill Capital Corp XI
0.00%+4.71%-8.32%+24.46%+1,289,999,900.00%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
0.00%+6.63%+8.84%+32.98%-21.80%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
2.33
Hold$7.0031.33% Upside
CCXI
Churchill Capital Corp XI
1.00
SellN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
2.43
Hold$14.878.75% Upside

Current Analyst Ratings Breakdown

Latest CCXI, AVIR, and HCM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/8/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Buy
9/3/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
Daiwa Securities Group Inc. logo
Daiwa Securities Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Buy
8/18/2026
CCXI
Churchill Capital Corp XI
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E) ➝ Sell (D)
8/13/2026
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$6.00 ➝ $7.00
8/3/2026
CCXI
Churchill Capital Corp XI
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E)
7/31/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C-) ➝ Sell (D)
7/23/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetNeutral$16.00 ➝ $14.00
7/17/2026
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/17/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D+) ➝ Hold (C-)
7/7/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$20.00 ➝ $17.00
6/29/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C-) ➝ Sell (D+)
(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/AN/AN/AN/A$3.53 per shareN/A
CCXI
Churchill Capital Corp XI
$37.20M24.74N/AN/AN/A∞
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$548.51M4.35$2.70 per share5.07$7.17 per share1.91
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$158.35M-$2.08N/AN/AN/AN/A-64.25%-57.12%11/11/2026 (Estimated)
CCXI
Churchill Capital Corp XI
N/A-$1.89N/AN/AN/AN/AN/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$456.91MN/AN/A62.14N/AN/AN/AN/AN/A

Latest CCXI, AVIR, and HCM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$0.5550-$0.41+$0.1450-$0.41$33.03 millionN/A
7/30/2026H1 2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$0.1450$0.05-$0.0950$0.05$304.16 million$139.14 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/AN/AN/AN/AN/A
CCXI
Churchill Capital Corp XI
N/AN/AN/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/A
8.13
8.13
CCXI
Churchill Capital Corp XI
N/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
0.06
5.64
5.50

Institutional Ownership

CompanyInstitutional Ownership
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
86.67%
CCXI
Churchill Capital Corp XI
81.09%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
8.82%

Insider Ownership

CompanyInsider Ownership
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
21.60%
CCXI
Churchill Capital Corp XI
8.30%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
3.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
5580.21 million62.88 millionOptionable
CCXI
Churchill Capital Corp XI
271.36 millionN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
1,796174.47 million168.19 millionNot Optionable

Recent News About These Companies

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Consensus Recommendation of "Hold" from Brokerages
September 18 at 8:43 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-hutchmed-china-limited-sponsored-adr-nasdaq-hcm-receives-consensus-recommendation-of-hold-from-brokerages-2026-09-18/
HUTCHMED (NASDAQ:HCM) Sees Large Volume Increase - Should You Buy?
September 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-hutchmed-nasdaq-hcm-sees-large-volume-increase-should-you-buy-2026-09-14/
HSBC Upgrades HUTCHMED (NASDAQ:HCM) to "Buy"
September 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31013742
HUTCHMED (NASDAQ:HCM) Upgraded by HSBC to "Buy" Rating
September 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-hutchmed-nasdaq-hcm-upgraded-by-hsbc-to-buy-rating-2026-09-08/
HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology Asset A830 - Slideshow
September 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4943635-hutchmed-china-limited-hcm-discusses-strategic-partnership-with-gsk-and-licensing-of-oncology
HUTCHMED (NASDAQ:HCM) Rating Increased to Buy at Daiwa Securities Group
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-hutchmed-nasdaq-hcm-rating-increased-to-buy-at-daiwa-securities-group-2026-09-03/
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/event-hutchmed-lands-gsk-deal-worth-up-to-13b-for-kras-egfr-cancer-therapy-2026-09-03/
HUTCHMED (NASDAQ:HCM) Shares Gap Up - What's Next?
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-hutchmed-nasdaq-hcm-shares-gap-up-whats-next-2026-09-03/
HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology Asset A830 Transcript
September 3, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4942785-hutchmed-china-limited-hcm-discusses-strategic-partnership-with-gsk-and-licensing-of-oncology
HUTCHMED Licenses HMPL-A830 To GSK In $1.295 Bln Deal For Cancer Therapy; Stock Up 14%
September 3, 2026  |  rttnews.comhttps://www.rttnews.com/3688056/hutchmed-licenses-hmpl-a830-to-gsk-in-1-295-bln-deal-for-cancer-therapy-stock-up-14.aspx
Hutchmed strikes licensing agreement with GSK
September 3, 2026  |  thepharmaletter.comT
Panmure and Cavendish reiterate buy on Hutchmed after GSK deal
September 3, 2026  |  proactiveinvestors.co.ukhttps://www.proactiveinvestors.co.uk/companies/news/1098046?snapi
HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal
September 3, 2026  |  proactiveinvestors.co.ukhttps://www.proactiveinvestors.co.uk/companies/news/1098034
HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal
September 3, 2026  |  proactiveinvestors.co.ukhttps://www.proactiveinvestors.co.uk/companies/news/1098034?snapi
HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug
September 3, 2026  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/hutchmed-china-signs-licensing-deal-with-gsk-experimental-solid-tumour-drug-2026-09-03/
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
September 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/03/3355629/0/en/hutchmed-announces-licensing-agreement-with-gsk-for-kras-egfr-antibody-conjugate-cancer-therapy.html
HUTCHMED (NASDAQ:HCM) Sees Large Volume Increase - Here's What Happened
September 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-hutchmed-nasdaq-hcm-sees-large-volume-increase-heres-what-happened-2026-09-02/
AstraZeneca, Hutchmed succeed in late-stage lung cancer trial for Orpathys, Tagrisso combo
September 1, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/astrazeneca-hutchmed-succeed-in-late-stage-lung-cancer-trial-for-orpathys-tagrisso-combo/ar-AA2bmfAS
HUTCHMED (NASDAQ:HCM) Shares Pass Above Fifty Day Moving Average - Here's Why
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-hutchmed-nasdaq-hcm-shares-pass-above-fifty-day-moving-average-heres-why-2026-09-01/
HUTCHMED Reports Positive Phase 3 SANOVO Data For ORPATHYS Plus TAGRISSO In EGFR-Mutant NSCLC
August 31, 2026  |  rttnews.comhttps://www.rttnews.com/3686757/hutchmed-reports-positive-phase-3-sanovo-data-for-orpathys-plus-tagrisso-in-egfr-mutant-nsclc.aspx
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing ...
August 30, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/hutchmed-announces-sanovo-trial-demonstrated-significant-progression-free-survival-benefit-of-orpathys-plus-tagrisso-in-treatment-na-ve-patients-with-met-overexpressing-egfr-mutated-lung-cancer-1036505134

New MarketBeat Followers Over Time

Media Sentiment Over Time

Atea Pharmaceuticals stock logo

Atea Pharmaceuticals NASDAQ:AVIR

$5.33 +0.07 (+1.33%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$5.32 -0.01 (-0.19%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Churchill Capital Corp XI NASDAQ:CCXI

$12.90 +0.83 (+6.88%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$12.92 +0.02 (+0.19%)
As of 09/18/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Churchill Capital Corp XI is a blank check company.

HUTCHMED stock logo

HUTCHMED NASDAQ:HCM

$13.67 -0.15 (-1.09%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$13.64 -0.03 (-0.25%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas